Koers GINO BIOW Nasdaq
Aandelen
DNA
US37611X1000
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 211 mln. 196 mln. | Omzet 2025 * | 282 mln. 262 mln. | Marktkapitalisatie | 1,68 mld. 1,56 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -540 mln. -501 mln. | Nettowinst (verlies) 2025 * | -496 mln. -461 mln. | EV/omzet 2024 * | 4,75 x |
Nettoliquiditeiten 2024 * | 676 mln. 628 mln. | Nettoliquiditeiten 2025 * | 550 mln. 510 mln. | EV/omzet 2025 * | 4 x |
K/w-verhouding 2024 * |
-2,42
x | K/w-verhouding 2025 * |
-2,93
x | Werknemers | 1.218 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 67,67% |
Recentste transcriptie over GINO BIOW
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Austin Che
FOU | Founder | - | 01-01-08 |
Founder | - | 01-01-08 | |
Reshma Shetty
FOU | Founder | 43 | 01-01-08 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Christian Henry
BRD | Director/Board Member | 56 | 16-09-21 |
Arie Belldegrun
BRD | Director/Board Member | 74 | 01-01-21 |
Marijn Dekkers
CHM | Chairman | 65 | 16-09-21 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+17,96% | 47,02 mld. | |
+48,77% | 41,86 mld. | |
+1,17% | 41,76 mld. | |
-4,27% | 28,8 mld. | |
+11,42% | 26,05 mld. | |
-21,39% | 19,15 mld. | |
+4,86% | 12,55 mld. | |
+27,29% | 12,34 mld. | |
-3,50% | 11,82 mld. |